Inactivating mutations in CREBBP and EP300 in GC B-cells decrease p53-mediated tumor suppression and enhance the proto-oncogenic activity of BCL-6.329,330CREBBP mutation is also associated with reduced MHC-II expression, which is a key element in antigen presentation, thereby promoting tumor escape from the immune system.331CREBBP and EP300 mutations were found in 65% and 15% of FL, respectively. The gene discussed is CREBBP; the disease is neoplasm.